Siderocalin fusion proteins enable a new 86Y/90Y theranostic approach†
a
Tyler A.
Bailey,
ab
Joshua J.
Woods,
a
Luis M.
Aguirre Quintana,
a
Jennifer N.
Wacker,
a
Rebecca J.
Abergel
*ab
Abstract
The mammalian protein siderocalin binds bacterial siderophores and their iron complexes through cation-π and electrostatic interactions, but also displays high affinity for hydroxypyridinone complexes of trivalent lanthanides and actinides. In order to circumvent synthetic challenges, the use of siderocalin-antibody fusion proteins is explored herein as an alternative targeting approach for precision delivery of trivalent radiometals. We demonstrate the viability of this approach in vivo, using the theranostic pair 90Y (β−, t1/2 = 64 h)/86Y (β+, t1/2 = 14.7 h) in a SKOV-3 xenograft mouse model. Ligand radiolabeling with octadentate hydroxypyridinonate 3,4,3-LI(1,2-HOPO) and subsequent protein binding were achieved at room temperature. The results reported here suggest that the rapid non-covalent binding interaction between siderocalin fusion proteins and the negatively charged Y(III)-3,4,3-LI(1,2-HOPO) complexes could enable purification-free, cold-kit labeling strategies for the application of therapeutically relevant radiometals in the clinic.
- This article is part of the themed collections: Chemical Biology of Metals and RSC Chemical Biology – Editors Choice Collection 2023
Please wait while we load your content...
